Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 19 of 26 · 1224 articles
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...
This study suggests that older-onset IBD is managed more conservatively and experiences fewer extraintestinal manifestations. Patients and clinicians should be aware that age can influence treatment choices and that...
Researchers are exploring targeted nanodelivery of miR-497 to reduce oxidative stress and shift immune cells toward tissue-repairing states — a novel preclinical strategy that could eventually lead to new treatments for...
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Medications. The original article is from Cureus.
Adherent-invasive E. coli (AIEC) is implicated in Crohn’s disease inflammation in some patients. This review maps possible ways to target AIEC specifically, which could lead to therapies that reduce infection-driven...
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
This label update lists safety concerns that affect people taking mesalamine for ulcerative colitis, including the need for kidney monitoring, signs of hypersensitivity, and rare but serious skin and liver reactions.
This FDA drug label explains when vitamin K (phytonadione) is indicated and how it should be dosed and monitored. People with IBD can develop vitamin K–related clotting problems because of malabsorption; the label...
RIPK proteins are central to cell-death and inflammatory pathways that can damage the intestinal lining in IBD. Understanding them could point to new treatments that more precisely block harmful inflammation while...
People with Crohn's disease and their clinicians often ask how different treatments affect cancer risk. This large nationwide study provides real-world estimates of absolute excess cancer cases by treatment group, which...
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
This trial tests mirikizumab (an anti–IL-23p19 biologic) alone and with an oral agent in adults with moderate–severe UC or CD, which could expand treatment options if later-phase trials are successful.
This trial tests whether adding an FXR agonist (LY4395089) to mirikizumab improves endoscopic response in people with moderate–severe Crohn's disease. Results could influence future combination treatment strategies and...
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
This trial tests a common real-world question: switching from IV induction to subcutaneous vedolizumab maintenance in adults with moderate-to-severe UC or CD and measures short-term remission and longer-term treatment...
Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
A new biologic (duvakitug) targeting TL1A showed higher clinical remission at 14 weeks than placebo in a phase 2b trial of adults with moderately to severely active ulcerative colitis, which could expand future treatment...
Patients and clinicians choosing first‑line biologic therapy for ulcerative colitis may find evidence here that vedolizumab can provide sustained clinical benefit and a favorable safety profile in a biologic‑naïve...
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
The study uses single-cell RNA sequencing to pinpoint genes and regulatory networks that might help explain IBD biology and suggest new biomarkers or repurposed drugs. That information could guide future research toward...
People taking isotretinoin may face a range of reported adverse events, including psychiatric and gastrointestinal issues and pregnancy-related risks. The study highlights signals (including IBD) that could affect...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Mesalamine, and Aminosalicylates. The original article is from Cureus.
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.
The report suggests adding acupuncture to anti-TNF therapy may improve short-term symptom control and mucosal healing and reduce early colectomy risk for a TCM-defined subgroup of ulcerative colitis patients, which could...
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
This study will collect real-world data on adults with moderate-to-severe ulcerative colitis who start upadacitinib, tracking symptom remission and imaging response over one to two years — information that can help...
This trial tests several investigational long-acting antibody treatments (as monotherapies and combinations) for adults with moderate to severe ulcerative colitis using histologic and clinical remission endpoints —...
This trial could expand approved treatment options for children with moderate to severe UC by testing the safety, pharmacokinetics, and maintenance dosing of risankizumab in pediatric age groups.
Mitochondrial dysfunction may be a central contributor to UC inflammation and is being targeted by new therapeutic strategies that could lead to different treatment approaches in the future.
The findings suggest that over three decades more patients receive medical prevention after ileocolic resection — including thiopurines and biologics — and that rates of needing a second surgery have fallen. This matters...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Alimentary pharmacology &...
A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and...
This study describes how IBD presents and early outcomes in children at a tertiary center, noting high rates of inflammation, nutritional problems, and early flares. Findings may help families and clinicians understand...
The study compares two oral steroid therapies used to induce remission in outpatient ulcerative colitis and reports similar short-term efficacy but different safety profiles — information that can inform treatment...
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
People with IBD face higher shingles risk, especially when immunosuppressed. This study provides prospective real-world data suggesting the recombinant zoster vaccine is well tolerated in IBD patients, including those on...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
An FDA label update for PYZCHIVA adds/clarifies that this ustekinumab product is indicated for Crohn's disease and ulcerative colitis and reiterates safety monitoring steps (for infections and TB) that matter to people...
The FDA label for XELJANZ/XELJANZ XR (tofacitinib) highlights serious safety risks and monitoring steps relevant to people with ulcerative colitis and other autoimmune conditions who may be using or considering this JAK...
The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...
This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...
This trial is testing duvakitug as a maintenance treatment for people with moderately to severely active ulcerative colitis who responded to an earlier study, which could expand treatment options if later shown to be...
